Action JAZZ JAZZ PHARMACEUTICALS PLC
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Jazz Pharmaceuticals plc

Actions

JAZZ

IE00B4Q5ZN47

Marché Fermé - Nasdaq
Autres places de cotation
 22:00:00 07/06/2024 		Varia. 5j. Varia. 1 janv.
112 USD +5,39 % Graphique intraday de Jazz Pharmaceuticals plc +6,46 % -8,90 %
06/06 Transcript : Jazz Pharmaceuticals plc Presents at Jefferies 2024 Global Healthcare Conference, Jun-06-2024 02:00 PM
01/06 Jazz Pharmaceuticals présente à l'ASCO 2024 les données de survie globale et de suivi à plus long terme de l'essai HERIZON-BTC-01 évaluant le zanidatamab dans le cancer des voies biliaires HER2-positif précédemment traité. CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Jazz Pharmaceuticals Presents Overall Survival and Longer Follow-Up Data from HERIZON-BTC-01 Trial Evaluating Zanidatamab in Previously Treated HER2-Positive Biliary Tract Cancer at ASCO 2024
Jazz Pharmaceuticals plc Announces Catherine Sohn, Pharm.D. Will Not Stand for Re-Election to the Board
Jazz Pharmaceuticals plc - Zanidatamab Granted Priority Review for HER2-Positive Metastatic Biliary Tract Cancer
Jazz Pharmaceuticals Showcases Pioneering Research in Sleep Medicine at SLEEP 2024
Jazz Pharmaceuticals Showcases Pioneering Research in Sleep Medicine at SLEEP 2024
Jazz Pharmaceuticals to Participate in Upcoming June Investor Conferences
Sector Update: Health Care Stocks Lean Lower Premarket Wednesday
Jazz Pharmaceuticals Says US FDA Grants Zanidatamab Priority Review to Treat HER2-Positive Metastatic Biliary Tract Cancer
Jazz Pharmaceuticals plc Announces the U.S. Food and Drug Administration Accepted and Granted Priority Review of the Biologics License Application for Zanidatamab
Jazz Pharmaceuticals Announces Collaboration with Life Science Cares to Improve the Wellbeing of Under Resourced Communities through Employee Volunteerism
US reclassification could drive fresh research funding into pot sector
Jazz Pharmaceuticals Insider Sold Shares Worth $548,250, According to a Recent SEC Filing
Jazz Pharmaceuticals : Corporate Overview
Jazz Pharmaceuticals : Announces First Quarter 2024 Financial Results
Jazz Pharmaceuticals Q1 Adjusted Earnings Decline, Revenue Rises; Reaffirms 2024 Outlook
(JAZZ) JAZZ PHARMACEUTICALS Forecasts Fiscal Year 2024 EPS Range $18.15 - $19.35
Earnings Flash (JAZZ) JAZZ PHARMACEUTICALS Reports Q1 Revenue $902M, vs. Street Est of $954.3M
Earnings Flash (JAZZ) JAZZ PHARMACEUTICALS Posts Q1 EPS $2.68, vs. Street Est of $4.18
Jazz: Q1 Earnings Snapshot
Jazz Pharmaceuticals to Participate in the BofA Securities 2024 Health Care Conference
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action JAZZ
  4. Actualités Jazz Pharmaceuticals plc
  5. Autres langues